Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials

References

• Cohen AT, Agnelli G, Anderson FA et al. Venous thromboembolism (VTE) in Europe. Thromb. Haemost.98, 756–764 (2007).
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest133, 381–453 (2008).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med.162, 1833–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Mismetti P, Laporte S, Zufferey P et al. Prevention of venous thrombembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J. Thromb. Haemost.2, 1058–1070 (2004).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Douketis JD. Extended duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet358, 9–15 (2001).
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Gallus AS, Cushner FD et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr. Med. Res. Opin.24, 87–97 (2008).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin induced thrombocytopenia. Chest133, 340–380 (2008).
   PubMedGoogle Scholar
• Perzborn E, Strassburger J, Wilmen A et al.In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939–an oral, direct Factor Xa inhibitor. J. Thromb. Haemost.3, 514–521 (2005).
   PubMed Web of Science ®Google Scholar
• Mueck W, Eriksson BI, Bauer KA et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet.47(3), 203–216 (2008).
   PubMed Web of Science ®Google Scholar
• Rivaroxaban summary of Product Characteristics, 2008.
   Google Scholar
• Turpie AG, Fisher WD, Bauer KA et al. BAY 59–7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A Phase II dose-ranging study. J. Thromb. Haemost.3, 2479–2486 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Dahl OE et al.; ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation114, 2374–2381 (2006).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris L, Dahl OE et al.; ODIXa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost.4, 121–128 (2006).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W et al. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban: an oral, direct Factor Xa inhibitor. Blood108, Abstract 905 (2006).
   Web of Science ®Google Scholar
• Bauer KS, Homering M, Berkowitz SD. Effects of age, weight, gender and renal function in a pooled analysis of four Phase III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery. Blood (ASH Annual Meeting Abstracts)112, 436(2008).
   Google Scholar
• Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med.358, 2765–2775 (2008).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet372, 31–39 (2008).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC et al. Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med.358, 2776–2785 (2008).
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Bauer KA, Davidson B et al. Once-daily oral rivaroxaban compared with subcutaneous enoxaparin every 12 hours for thromboprophylaxis after total knee replacement: RECORD 4. Blood (ASH Annual Meeting Abstracts)112, 35(2008).
   Google Scholar
• Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(Suppl. 3), S338–S400 (2004).
   PubMedGoogle Scholar
• Kubitza D, Becka M, Mueck W et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor – are not affected by aspirin. J. Clin. Pharmacol.46, 981–990 (2006).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59–7939 and digoxin. J. Clin. Pharmacol.46(Abstract), 702(2006).
   Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J. Clin. Pharmacol.46, 549–558 (2006).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Mueck W, Becka M. No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and atorvastatin. Pathophysiol. Haemost. Thromb.36, A40(2008).
   Google Scholar